Testing a new immune cell therapy for systemic sclerosis (scleroderma)
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of systemic sclerosis (scleroderma).
- Your disease must be early and active, with skin, lung, or heart involvement.
- You must not have had CAR T-cell therapy or an organ/stem cell transplant before.
- You must not have an active infection or severe organ problems that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new treatment called C-CAR168 for people with certain autoimmune diseases that have not improved with standard therapies. It aims to see if this treatment can help control the disease.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.